• US Preventive Services Task Force, Michael J Barry, Wanda K Nicholson, Michael Silverstein, David Chelmow, Tumaini Rucker Coker, Karina W Davidson, Esa M Davis, Katrina E Donahue, Carlos Roberto Jaén, Li Li, Gbenga Ogedegbe, Lori Pbert, Goutham Rao, John M Ruiz, James J Stevermer, Joel Tsevat, Sandra Millon Underwood, and John B Wong.
• Harvard Medical School, Boston, Massachusetts.
• JAMA. 2023 Jun 20; 329 (23): 205720672057-2067.

ImportanceMajor depressive disorder (MDD), a common mental disorder in the US, may have substantial impact on the lives of affected individuals. If left untreated, MDD can interfere with daily functioning and can also be associated with an increased risk of cardiovascular events, exacerbation of comorbid conditions, or increased mortality.ObjectiveThe US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate benefits and harms of screening, accuracy of screening, and benefits and harms of treatment of MDD and suicide risk in asymptomatic adults that would be applicable to primary care settings.PopulationAsymptomatic adults 19 years or older, including pregnant and postpartum persons. Older adults are defined as those 65 years or older.Evidence AssessmentThe USPSTF concludes with moderate certainty that screening for MDD in adults, including pregnant and postpartum persons and older adults, has a moderate net benefit. The USPSTF concludes that the evidence is insufficient on the benefit and harms of screening for suicide risk in adults, including pregnant and postpartum persons and older adults.RecommendationThe USPSTF recommends screening for depression in the adult population, including pregnant and postpartum persons and older adults. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for suicide risk in the adult population, including pregnant and postpartum persons and older adults. (I statement).

18 keywords...

hide…